Literature DB >> 22761487

How to use... alkaline phosphatase in neonatology.

Robert J Tinnion1, Nicholas D Embleton.   

Abstract

Alkaline phosphatase (ALP) is regularly measured in clinical practice. Changes in serum levels are observed in a number of clinical conditions. In neonatology, it has been proposed as a useful marker for both a diagnosis and an indication of the severity of metabolic bone disease (MBD) in infants born preterm. Nutritional practices, aimed at reducing the occurrence or severity of MBD, have led to ALP being proposed as a stand-alone means of monitoring treatment. The current evidence does not support this use: ALP only achieves usefulness in a diagnostic and monitoring capacity when combined with other serum and imaging techniques.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761487     DOI: 10.1136/archdischild-2012-301633

Source DB:  PubMed          Journal:  Arch Dis Child Educ Pract Ed        ISSN: 1743-0585            Impact factor:   1.309


  17 in total

1.  Is additional oral phosphate supplementation for preterm infants necessary: an assessment of clinical audit.

Authors:  Stewart Watts; Helen Mactier; June Grant; Eilidh Cameron Nicol; Alexander Balfour Mullen
Journal:  Eur J Pediatr       Date:  2013-05-24       Impact factor: 3.183

2.  Impact of Early Versus Late Diuretic Exposure on Metabolic Bone Disease and Growth in Premature Neonates.

Authors:  Lucas E Orth; Keliana L O'Mara
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jan-Feb

Review 3.  Multi-nutrient fortification of human milk for preterm infants.

Authors:  Jennifer Ve Brown; Luling Lin; Nicholas D Embleton; Jane E Harding; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2020-06-03

4.  [Expert consensus on the follow-up management of bronchopulmonary dysplasia in preterm infants after discharge].

Authors: 
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-05-15

Review 5.  Hypophosphatasia: Biological and Clinical Aspects, Avenues for Therapy.

Authors:  Jean Pierre Salles
Journal:  Clin Biochem Rev       Date:  2020-02

6.  Parathyroid hormone as a marker for metabolic bone disease of prematurity.

Authors:  A Moreira; L Swischuk; M Malloy; D Mudd; C Blanco; C Geary
Journal:  J Perinatol       Date:  2014-05-29       Impact factor: 2.521

7.  Bone status in preterm infant: influences of different nutritional regimens and possible markers of bone disease.

Authors:  M Meneghelli; A Pasinato; S Salvadori; P Gaio; M Fantinato; V Vanzo; F De Terlizzi; G Verlato
Journal:  J Perinatol       Date:  2016-01-14       Impact factor: 2.521

8.  Bone mineral density and osteoporosis after preterm birth: the role of early life factors and nutrition.

Authors:  Claire L Wood; Alexander M Wood; Caroline Harker; Nicholas D Embleton
Journal:  Int J Endocrinol       Date:  2013-04-10       Impact factor: 3.257

9.  Increasing fetal ovine number per gestation alters fetal plasma clinical chemistry values.

Authors:  Micaela Zywicki; Sharon E Blohowiak; Ronald R Magness; Jeffrey L Segar; Pamela J Kling
Journal:  Physiol Rep       Date:  2016-08

10.  Cord Blood Alkaline Phosphatase as an Indicator of Neonatal Jaundice.

Authors:  Mousa Ahmadpour-Kacho; Yadollah Zahed Pasha; Mohsen Haghshenas; Zahra Akbarian Rad; Alireza Firouzjahi; Ali Bijani; Abdollah Dehvari; Mehrangiz Baleghi
Journal:  Iran J Pediatr       Date:  2015-10-06       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.